Spotlight on Subcutaneous Recombinant Interferon-β-1a (Rebif®) in Relapsing-Remitting Multiple Sclerosis

@article{Murdoch2012SpotlightOS,
  title={Spotlight on Subcutaneous Recombinant Interferon-$\beta$-1a (Rebif{\textregistered}) in Relapsing-Remitting Multiple Sclerosis},
  author={David L. Murdoch and Katherine A. Lyseng-Williamson},
  journal={BioDrugs},
  year={2012},
  volume={19},
  pages={323-325}
}
Subcutaneous recombinant interferon-β-1a (Rebif®) 22 or 44μg three times weekly is a valuable option in the first-line treatment in patients with relapsing-remitting multiple sclerosis. It has shown benefits on outcome measures related to relapses, progression of disability, and magnetic resonance imaging in clinical trials. A significant efficacy advantage for subcutaneous interferon-β-1a three times weekly over intramuscular interferon-β-1a 30μg once weekly was shown at 24 and 48 weeks. The… 
ALPHA LIPOIC ACID AS ADD-ON THERAPY TO SUBCUTANEOUS INTERFE RON Β1 A FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS : A PILOT STUDY
TLDR
A pilot study to assess the efficacy of ALA as add-on therapy to subcutaneous IFN β-1a in relapsing-remitting multiple sclerosis patients found no beneficial effect and future larger studies are needed to investigate whether higher ALA doses could be beneficial.
Magnetic Resonance Imaging Reveals Therapeutic Effects of Interferon-Beta on Cytokine-Induced Reactivation of Rat Model of Multiple Sclerosis
  • S. Serres, C. Bristow, D. Anthony
  • Biology, Medicine
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism
  • 2013
TLDR
Findings indicate a central role for peripheral IL-1β expression in the mechanism of MS lesion reactivation and that the therapeutic effects of IFN-β may, at least in part, reflect suppression of the effects of peripheral inflammation on MS lesions pathogenesis.
Respuestas rápidas a la pandemia de COVID-19 a través de la ciencia y la colaboración global: el ensayo clínico Solidaridad
TLDR
SOLIDARITY is a mega clinical trial that recruited thousands of subjects with moderate to severe disease, who were randomly assigned to one of the treatment groups under evaluation, including hydroxychloroquine, lopinavir/ritonavir associated or not with interferon; or remdesivir compared to standard therapy.
Improving Immunotherapy Through Glycodesign
TLDR
How optimizing glycosylation through a variety of glycoengineering strategies provides enticing opportunities to not only avoid past pitfalls, but also to substantially improve immunotherapies including antibodies and recombinant proteins, and cell-based therapies is described.
Impact of IFN‐β and LIF overexpression on human adipose‐derived stem cells properties
TLDR
An hADSC population stably overexpressed IFN‐β and LIF cytokines is successfully constructed and could be subjected for further evaluations in experimental autoimmune encephalomyelitis mice model.
Inflammatory pathways are central to posterior cerebrovascular artery remodelling prior to the onset of congenital hypertension
  • Dawid Walas, K. Nowicki-Osuch, J. Paton
  • Medicine, Biology
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism
  • 2018
TLDR
Data indicate that inflammatory driven cerebral artery remodelling occurs prior to the onset of hypertension and may be a trigger elevating systemic blood pressure in genetically programmed hypertension.
Microglial phagocytosis in aging and Alzheimer's disease
TLDR
This review will summarize the current knowledge on how phagocytosis is executed and affected by aging or in age‐associated neurological disorders, such as Alzheimer's disease (AD) and where relevant in other neurodegenerative diseases.
THE ROLE OF GLYCOSYLATION IN IMMUNOTHERAPY
  • 2018

References

SHOWING 1-10 OF 24 REFERENCES
Haematological Effects of Interferon-β-1a (Rebif®) Therapy in Multiple Sclerosis
TLDR
Although haematological abnormalities are common and dose-related in patients with MS receiving interferon-β-1a, the events are mainly mild and transient, with little impact on adherence to therapy.
Long-Term Cost Effectiveness of Interferon-β-1a in the Treatment of Relapsing-Remitting Multiple Sclerosis
TLDR
This analysis indicated that IFNβ-1a 44μg subcutaneously three times weekly is cost effective in RRMS and that treatment becomes increasingly cost effective over time.
Randomized, comparative study of interferon β-1a treatment regimens in MS
TLDR
IFNβ-1a 44 μg subcutaneously tiw was more effective than IFNβ -1a 30 μg IM qw on all primary and secondary outcomes investigated after 24 and 48 weeks of treatment.
Hepatic Reactions During Treatment of Multiple Sclerosis with Interferon-β-1a
TLDR
Asymptomatic hepatic dysfunction is common in patients with multiple sclerosis who are treated with interferon-β-1a, and is dose related, with little impact on adherence to therapy, although rare serious events can occur.
Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study.
TLDR
Patients receiving interferon beta-1a improved on clinical and MRI disease measures when they changed from 30 microg QW to 44 microg TIW, and had fewer active lesions on T2-weighted MRI compared with before the transition, whereas those continuing the 44-microgTIW regimen had no significant change in T2 active lesions.
PRISMS-4: Long-term efficacy of interferon-β-1a in relapsing MS
TLDR
Clinical and MRI benefit continued for both doses up to 4 years, with evidence of dose response, and outcomes were consistently better for patients treated for 4 years than for patients in crossover groups.
PRISMS-4: Long-term efficacy of interferon-&bgr;-1a in relapsing MS
TLDR
Clinical and MRI benefit continued for both doses up to 4 years, with evidence of dose response, and outcomes were consistently better for patients treated for 4 years than for patients in crossover groups.
Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis
TLDR
The potential development ofNAbs is an important consideration in selection and monitoring treatment of MS, and long-term prospective studies are needed to further define the clinical effects of NAbs on patients receiving disease-modifying therapies for MS.
...
...